GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of week 17 check-in — 4kg down, fatigue manageable, one thing confusing me — 32 comments in the full submission. View in context.
3.9k
c/cagrilintide·submitted 2 years ago by u/lucia_bruun

week 17 check-in — 4kg down, fatigue manageable, one thing confusing me

Labbranch of 6 comments

Here it is: week 17 check-in — 4kg down, fatigue manageable, one thing confusing me. One person, one log, no control group, so read it accordingly. Hard numbers: week 17 and 4kg. Anything softer than that is flagged as an impression. Reading the trial literature on this without misleading yourself. Separate the…

Read the full submission and all 32 comments →

This branch

6 comments, started 2 years ago
u/amylin_amyMOD612 points·2 years ago

Retitled to distinguish the combination arm from the monotherapy arm, which the original ran together.

replysharereportpermalink
u/slow_logbook_notes30781 points·2 years ago

Which receptor family are you attributing that effect to?

replysharereportpermalink
u/elin_lundgren431 points·2 years ago

Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.

replysharereportpermalink
u/rafael_krastev547 points·2 years ago

Correction: that is the combination programme, not the monotherapy readout.

Adding the standing caveat — nothing here is approved standalone and research material is not for human use.

replysharereportpermalink
u/ms_fragmenter138 points·2 years ago

nothing here is approved as a standalone product and research material is not for human use

replysharereportpermalink
u/lucia_bruunOP454 points·2 years ago·edited

Which receptor family are you attributing that effect to?

This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.

replysharereportpermalink

← back to the whole thread

About c/cagrilintide

Amylin analog pharmacology and the CagriSema combination: why amylin and GLP-1 co-agonism produces a different satiety profile, the REDEFINE readouts, and the very limited pool of people handling cagrilintide as research material.

19kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/cagrilintide
c/cagrilintide rules
  1. Amylin is not a GLP-1. Posts conflating them get corrected.
  2. CagriSema ratios in trials are fixed-dose. Do not extrapolate to self-mixing.
  3. Not approved anywhere. Keep posts descriptive, not instructional.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/amylin_amyu/incretin_ivyu/ledger_mod
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →